Local News: Lynchburg, TN 

 | 

Sign Up

 | 

Sign In

Advertisment

Novartis News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Novartis News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Novartis News

News on Novartis continually updated from thousands of sources around the net.

8 hrs ago | SYS-CON MEDIA

Video: Novartis Launches Prevacid(R)24HR Over-the-Counter for Full...

Novartis announced the availability of PrevacidA 24HR over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn.

Comment?

Related Topix: Biotech, Prevacid, Lansoprazole (generic), Medication, Food and Drug Administration

Wed Nov 11, 2009

Swissinfo

Swiss left unimpressed by swine flu policy

Government calls for at-risk individuals to get vaccinated against H1N1 have fallen largely on deaf Swiss ears, with many believing the threat is exaggerated.

Comment?

Related Topix: H1N1 Influenza / Swine Flu, Health, Biotech, Medicine, Influenza

Tue Nov 10, 2009

BioSpace

Novartis Corporation to Acquire Majority Stake in Hard To Treat...

SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseases www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, 9, H1N1 Influenza / Swine Flu, Marketing

Mon Nov 09, 2009

GlobeNewswire

Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences

Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Human Genome Sciences .

Comment?

Related Topix: Biotech, Medicine, Human Genome Sciences, Healthcare Industry, Healthcare Law, Law, Bristol Myers Squibb, Lupus, Health

Sat Nov 07, 2009

Fox News

Winners & Losers in Fight Against the Flu

For most of us, the very mention of "swine flu" brings about feelings of fear, or at the very least thoughts of fevers, congestion, annoying coughs and stuffy noses.

Comment?

Related Topix: H1N1 Influenza / Swine Flu, Health, Epidemic, Natural Disasters, Biotech, SanofiSynthlabo, Medicine, GlaxoSmithKline, Healthcare Industry

MediLexicon

Novartis Receives Regulatory Approval In Germany For Celtura , A Cell ...

Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A 2009 monovalent vaccine, Celtura.

Comment?

Related Topix: Biotech, Medicine, Influenza, Health, H1N1 Influenza / Swine Flu, Epidemic, Natural Disasters, Marketing

Fri Nov 06, 2009

Pharmaceutical Technology

Novartis to invest $1 billion in China R&D institute

Novartis plans to invest $1 billion during the next 5 years to increase R&D activities in China, including a significant expansion of The Novartis Institute of BioMedical Research in Shanghai.

Comment?

Related Topix: Biotech

Bloomberg.com - Asia

HSBC, Roche, Novartis Under Probe in Korea Over Large-Scale Tamiflu Sales

Roche Holdings AG , maker of the Tamiflu antiviral treatment, is under investigation in South Korea for its alleged involvement in illegal sales of the drug as the number of swine flu cases jumped.

Comment?

Related Topix: South Korea, World News, Asia, Biotech,

Thu Nov 05, 2009

The Oregonian

Germany OK's Novartis swine flu vaccine from cells

BASEL, Switzerland - Swiss pharmaceutical company Novartis AG said Thursday it has received regulatory approval in Germany for a new swine flu vaccine produced using cell cultures instead of egg-based methods.

Comment?

Related Topix: Biotech, H1N1 Influenza / Swine Flu, Health, Medicine, Influenza, US Politics, US News

The Biotech Stock Blog

Novartis Joins Global Interest in Vaccines with Increased China Investments

Novartis continued its mega-investments in China by announcing it will spend $250 million to expand its global technical center in Changshu, and it will also pay $125 million to buy a 85% stake in a privately held China vaccine company, Zhejiang Tianyuan.

Comment?

Related Topix: Biotech, World News, China,

Wed Nov 04, 2009

CSRwire.com

Novartis Honors Six Energy Saving Programs as Important Investments into a Sustainable Future

Six projects - from Austria, Germany, Switzerland and the USA - recognized by this year's Novartis Energy Excellence Awards Substantial energy savings and reduction of greenhouse-gas emissions achieved by record number of project submissions Novartis has announced the winners of its annual Energy Excellence Awards , which recognizes associates who ...

Comment?

Related Topix: Biotech

Pharmaceutical Processing

Novartis to Buy Majority Stake in China's Zhejiang Tianyuan Bio-Pharmaceutical Company

Ltd. Privately-held Tianyuan sells vaccines against diseases such as hemorrhagic fever with renal syndrome, or HFRS, caused by hantaviruses, and conducts research into "various preventable viral and bacterial diseases," Novartis said.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

People's Daily Online

Novartis announces new investment in China to increase R&D activities

Swiss pharmaceutical giant Novartis announced on Tuesday that it would invest 1 billion U.S. dollars in China over the next five years, with a main aim to increase R&D activities in the country.

Comment?

Related Topix: Biotech

Tue Nov 03, 2009

The Motley Fool

This Stable Stock Could Still Surprise

I last recommended that Fools take a look at consumer-staples company Clorox back in June.

Comment?

Related Topix: Clorox, Household Products, Financial Markets, H1N1 Influenza / Swine Flu, Health, Biotech, SanofiSynthlabo, AstraZeneca Group

Shanghai Daily

Novartis to invest additional US$1b

NOVARTIS AG yesterday signed a deal with the Shanghai government to invest an additional US$1 billion over five years in the drug maker's third-biggest research and development center in the world.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Nov 02, 2009

The Motley Fool

Earnings? Yawn. Trial Data? Moving

Technically, Human Genome Sciences has one drug for sale, but it's between shipments of ABthrax, its anthrax treatment, to the government, so Human Genome's earnings release Thursday was rather dry.

Comment?

Related Topix: Biotech, Medicine, Human Genome Sciences, Healthcare Industry, GlaxoSmithKline, InterMune, Teva Pharmaceutical Industries

Sat Oct 31, 2009

The Motley Fool

Of One-Time Gains and Pipelines

The focus of AstraZeneca 's earnings report illustrates the nature of polar opposites with one-time gains and new drugs.

Comment?

Related Topix: Biotech, AstraZeneca Group, H1N1 Influenza / Swine Flu, Health, Medicine, Influenza, GlaxoSmithKline, Bristol Myers Squibb, Healthcare Industry

Fri Oct 30, 2009

Washington Business Journal

Human Genome Sciences narrows loss

Human Genome Sciences Inc. narrowed its third-quarter losses by a third, partly by increasing its revenue by 61 percent.

Comment?

Related Topix: Biotech, Medicine, Human Genome Sciences, Healthcare Industry, GlaxoSmithKline, Hepatitis, Health, Lupus

Bioscience Technology

Novartis not licensing Idenix's hepatitis C drug

Idenix Pharmaceuticals Inc. says its partner Novartis AG will not move ahead with optioning a license to a potential hepatitis C drug.

Comment?

Related Topix: Biotech, Hepatitis, Medicine, Healthcare Industry

Reuters

Vaccine firms say on track to meet U.S. H1N1 orders

Drugmakers say they are on track to deliver as much H1N1 swine flu vaccine to the United States as they promised, despite concerns over production.

Comment?

Related Topix: H1N1 Influenza / Swine Flu, Health, Medicine, Influenza, Biotech

Lynchburg Jobs

Also on Topix